TD Cowen cuts rating on Illumina stock to hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Barclays Downgrades Illumina (ILMN) to Underweight
February 10, 2025 6:13 AM ESTBarclays analyst Luke Sergott downgraded Illumina (NASDAQ: ILMN) from Equalweight to Underweight with a price target of $100.00 (from $130.00).
The analyst comments "Overall, we view ILMN as a great business with a technological edge that has matured along with the market it created. We think that it is a normal Tools business not unlike other mature genomics / proteomics markets like PCR and mass spec. These are solid MSD topline growers with an oligopoly... More
